Why Zoetis, Akamai, and Seagate Shares Dropped
Zoetis (ZTS) shares fell nearly 6% to $72.66 after Q2 results. The company reported weaker vet clinical visits and lower net average selling prices, which could pressure margins. Akamai (AKAM) traded near the lower end of its range after Q2 revenue rose 5.8% to $1.1B and cloud bookings totaled $2.8B. Seagate (STX) dropped to $812.76 after Q2 non-GAAP EPS of $5.71 and revenue up 48.8% to $3.63B.
How this was made
The 30-second read
Why it matters
For ZTS, the key driver is weaker vet clinical visits and potential ASP-driven margin pressure. For AKAM, the key driver is selling despite revenue growth and large cloud infrastructure bookings. For STX, the key driver is profit-taking and momentum after a strong run, despite a Q2 beat.
Market read
This is a post-earnings reaction wrap for three large-cap names, with the newest actionable element being the stated price weakness and the cited earnings-linked drivers.
What to watch
The article does not provide guidance, margin figures, or management commentary, so traders may be over-weighting the narrative versus the full earnings release details.
Background
The piece frames three separate stock declines as reactions to Q2 results and expectation gaps, citing specific revenue/EPS and demand indicators.
Ticker impact
Zoetis shares fell nearly 6% after Q2 results, with vet clinical visits down and lower net average selling price pressuring margins.
Bearish bias for the next few sessions as traders digest margin risk from the Q2 setup.
The article links the selloff directly to Q2 outcomes (visits down, ASP risk) rather than a generic market move.
Akamai traded at the low end of its $110 to $130 range despite Q2 revenue up 5.8% and $2.8B cloud bookings.
Choppy-to-bearish near term while price remains pinned near the lower end of the stated range.
The text attributes selling to the mismatch between bookings and investor expectations, but provides no new guidance or margin detail.
Seagate pulled back sharply after topping $1,145, with the stock closing at $812.76 and a possible retest to $750 if momentum worsens.
Potential further downside toward the cited $750 retest level if selling accelerates.
The article is partly technical (retest level) and lacks incremental fundamental disclosures beyond the already-reported quarter results.
Market effects
Pet care demand sensitivity to inflation and enterprise security spending expectations are both reinforced by the negative reactions.
No explicit regional macro driver is provided beyond general inflation pressure on pet owners.
Limited global linkage; the catalysts are company-specific Q2 reactions.
Counterpoint
Revenue growth and bookings for Akamai, plus Seagate’s revenue and EPS beat, could indicate the selloff is positioning-related rather than a fundamental deterioration.
Key entities
- public_companyZoetis
Pet drug supplier whose Q2 reaction is tied to falling vet clinical visits and ASP/margin risk.
- public_companyAkamai
Cloud infrastructure and security provider whose Q2 revenue and bookings did not prevent a stock drop.
- public_companySeagate Technology
Hard disk supplier whose Q2 beat failed to impress and whose stock is described as in negative momentum.
